Huanglian‑Houpo drug combination ameliorates H1N1‑induced mouse pneumonia via cytokines, antioxidant factors and TLR/MyD88/NF‑κB signaling pathways

Zhang,Li; Zhang,Bei; Wang,Linjing; Lou,Mingwu; Shen,Yunxia

doi:10.3892/etm.2021.9845

Huanglian‑Houpo drug combination ameliorates H1N1‑induced mouse pneumonia via cytokines, antioxidant factors and TLR/MyD88/NF‑κB signaling pathways

Authors:
- Li Zhang
- Bei Zhang
- Linjing Wang
- Mingwu Lou
- Yunxia Shen
View Affiliations

Affiliations: Department of Radiology, Shenzhen Clinical Medical School, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518116, P.R. China, Department of Radiology, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong 518112, P.R. China
Published online on: February 26, 2021 https://doi.org/10.3892/etm.2021.9845
Article Number: 428
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Huanglian‑Houpo drug combination (HHDC) is a classical traditional Chinese medicine that has been effectively used to treat seasonal colds and flu. However, no systematic studies of the effects of HHDC on H1N1 influenza infection and the associated mechanisms have been reported. The aim of the present study was to determine the anti‑H1N1 influenza effects of HHDC and explore the underlying mechanisms. A mouse model of H1N1‑induced pneumonia was established and the mice were treated with HHDC (4, 8 and 16 g/kg) for 5 days after viral challenge. The antiviral effects of HHDC and the underlying mechanisms in the mice were investigated and evaluated with respect to inflammation, oxidative stress and Toll‑like receptor (TLR)/myeloid differentiation factor (MyD88)/nuclear factor (NF)‑κB signaling pathways. HHDC provided significant protection against weight loss and reduced the H1N1 viral load in the lungs. In addition, HHDC significantly decreased the lung index and increased the spleen and thymus indices of the H1N1‑infected mice. HHDC also significantly ameliorated the histopathological changes of pneumonia, decreased serum levels of the cytokines interleukin (IL)‑6, tumor necrosis factor‑α and interferon‑γ, and increased the serum level of IL‑2. Moreover, HHDC significantly increased the levels of the antioxidant factors superoxide dismutase and glutathione, and reduced the serum level of nitric oxide. Furthermore, the mRNA and protein expression levels of TLR3, TLR7, MyD88, NF‑κB p65 and tumor necrosis factor receptor‑associated factor 3 in the lung tissues were significantly decreased by HHDC. These findings suggest that HHDC directly inhibited H1N1 infection in vivo and exerted a therapeutic effect on influenza‑induced pneumonia in mice by modulating cytokines, antioxidant factors and TLR/MyD88/NF‑κB signaling pathways.

View Figures

View References

1	Fasanmi OG, Odetokun IA, Balogun FA and Fasina FO: Public health concerns of highly pathogenic avian influenza H5N1 endemicity in Africa. Vet World. 10:1194–1204. 2017.PubMed/NCBI View Article : Google Scholar
2	Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, et al: Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antiviral Res. 132:178–185. 2016.PubMed/NCBI View Article : Google Scholar
3	Lansbury LE, Smith S, Beyer W, Karamehic E, Pasic-Juhas E, Sikira H, Mateus A, Oshitani H, Zhao H, Beck CR and Nguyen-Van-Tam JS: Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine. 35:1996–2006. 2017.PubMed/NCBI View Article : Google Scholar
4	Song FX, Zhou J, Shi YX, Zhang ZY, Feng F, Zhou JJ and Wang QL: Bedside chest radiography of novel influenza A (H7N9) virus infections and follow-up findings after short-time treatment. Chin Med J (Engl). 126:4440–4443. 2013.PubMed/NCBI
5	Fan VY, Jamison DT and Summers LH: Pandemic risk: How large are the expected losses? Bull World Health Organ. 96:129–134. 2018.PubMed/NCBI View Article : Google Scholar
6	Petrova VN and Russell CA: The evolution of seasonal influenza viruses. Nat Rev Microbiol. 16:47–60. 2018.PubMed/NCBI View Article : Google Scholar
7	World Health Organization, Up to 650,000 people die of respiratory diseases linked to seasonal flu each year. http://www.who.int/mediacentre/news/releases/2017/seasonal-flu/en/. Accessed 13 October 2018.
8	Paules CI, Marston HD, Eisinger RW, Baltimore D and Fauci AS: The pathway to a universal influenza vaccine. Immunity. 47:599–603. 2017.PubMed/NCBI View Article : Google Scholar
9	Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC and Nicholson KG: Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review. J Infect. 62:14–25. 2011.PubMed/NCBI View Article : Google Scholar
10	Han X, Zhang DK, Guo YM, Feng WW, Dong Q, Zhang CE, Zhou YF, Liu Y, Wang JB, Zhao YL, et al: Screening and evaluation of commonly-used anti-influenza Chinese herbal medicines based on anti-neuraminidase activity. Chin J Nat Med. 14:794–800. 2016.PubMed/NCBI View Article : Google Scholar
11	Kumar B, Asha K, Khanna M, Ronsard L, Meseko CA and Sanicas M: The emerging influenza virus threat: Status and new prospects for its therapy and control. Arch Virol. 163:831–844. 2018.PubMed/NCBI View Article : Google Scholar
12	Peng XQ, Zhou HF, Zhang YY, Yang JH, Wan HT and He Y: Antiviral effects of Yinhuapinggan granule against influenza virus infection in the ICR mice model. J Nat Med. 70:75–88. 2016.PubMed/NCBI View Article : Google Scholar
13	Li JH, Wang RQ, Guo WJ and Li JS: Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): J Chin Med. Assoc. 79:281–291. 2016.PubMed/NCBI View Article : Google Scholar
14	Liu X, Zhang M, He L and Li Y: Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev. 10(CD004882)2012.PubMed/NCBI View Article : Google Scholar
15	Ma LL, Ge M, Wang HQ, Yin JQ, Jiang JD and Li YH: Antiviral activities of several oral traditional Chinese medicines against influenza viruses. Evid Based Complement Alternat Med. 2015(367250)2015.PubMed/NCBI View Article : Google Scholar
16	Zhang HH, Yu WY, Li L, Wu F, Chen Q, Yang Y and Yu CH: Protective effects of diketopiperazines from Moslae Herba against influenza A virus-induced pulmonary inflammation via inhibition of viral replication and platelets aggregation. J Ethnopharmacol. 215:156–166. 2018.PubMed/NCBI View Article : Google Scholar
17	Cheng TF, Jia YR, Zuo Z, Dong X, Zhou P, Li P and Li F: Quality assessment of traditional Chinese medicine herb couple by high-performance liquid chromatography and mass spectrometry combined with chemometrics. J Sep Sci. 39:1223–1231. 2016.PubMed/NCBI View Article : Google Scholar
18	Pan T, Cheng TF, Jia YR, Li P and Li F: Anti-rheumatoid arthritis effects of traditional Chinese herb couple in adjuvant-induced arthritis in rats. J Ethnopharmacol. 205:1–7. 2017.PubMed/NCBI View Article : Google Scholar
19	Zhang ZJ: Treatise on Febrile Diseases. People's Health Publishing House, Beijing, 2005.
20	Hsieh CF, Lo CW, Liu CH, Lin S, Yen HR, Lin TY and Horng JT: Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. J Ethnopharmacol. 143:57–67. 2012.PubMed/NCBI View Article : Google Scholar
21	Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, Cheng PL, Yutao W, Zheng J, Yang Z and Zhang F: The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 17(130)2017.PubMed/NCBI View Article : Google Scholar
22	Wu QF, Zhu WR, Yan YL, Zhang XX, Jiang YQ and Zhang FL: Anti-H1N1 influenza effects and its possible mechanism of Huanglian Xiangru Decoction. J Ethnopharmacol. 185:282–288. 2016.PubMed/NCBI View Article : Google Scholar
23	Chen G, Wu QF, Yan YL, Qian XW and Zhang XX: College of Pharmaceutical Science, Zhejiang Chinese Medical University. Data analysis for compatibility of Rhizoma Coptidis-cortex magnoliae officinalis herbal pair. Chin J Exp Traditional Med Formul. 22:211–216. 2016.
24	Wang N, Tan HY, Li L, Yuen MF and Feng Y: Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. J Ethnopharmacol. 176:35–48. 2015.PubMed/NCBI View Article : Google Scholar
25	Li H, Liu X, Zhu Y, Liu Y and Wang Y: Magnolol derivative 002C-3 protects brain against ischemia-reperfusion injury via inhibiting apoptosis and autophagy. Neurosci Lett. 588:178–183. 2015.PubMed/NCBI View Article : Google Scholar
26	Park H, Kim HS, Eom SJ, Kim KT and Paik HD: Antioxidative and anticanceric activities of magnolia (Magnolia denudata) flower petal extract fermented by pediococcus acidilactici KCCM 11614. Molecules. 20:12154–12165. 2015.PubMed/NCBI View Article : Google Scholar
27	Wu XN, Yu CH, Cai W, Hua J, Li SQ and Wang W: Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice. J Ethnopharmacol. 134:191–194. 2011.PubMed/NCBI View Article : Google Scholar
28	Enkhtaivan G, Muthuraman P, Kim DH and Mistry B: Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. Bioorg Med Chem. 25:5185–5193. 2017.PubMed/NCBI View Article : Google Scholar
29	Wu Y, Li JQ, Kim YJ, Wu J, Wang Q and Hao Y: In vivo and in vitro antiviral effects of berberine on influenza virus. Chin J Integr Med. 17:444–452. 2011.PubMed/NCBI View Article : Google Scholar
30	Saganuwan SA: A modified arithmetical method of Reed and Muench for determination of a relatively ideal median lethal dose (LD₅₀). Afr J Pharm Pharmacol. 5:1543–1546. 2011.
31	Zhang XX, Wu QF, Yan YL and Zhang FL: Inhibitory effects and related molecular mechanisms of total flavonoids in Mosla chinensis Maxim against H1N1 influenza virus. Inflamm Res. 67:179–189. 2018.PubMed/NCBI View Article : Google Scholar
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
33	Lester SN and Li K: Toll-like receptors in antiviral innate immunity. J Mol Biol. 426:1246–1264. 2014.PubMed/NCBI View Article : Google Scholar
34	Robinson KM, Kolls JK and Alcorn JF: The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 34:59–67. 2015.PubMed/NCBI View Article : Google Scholar
35	Zhu H, Lu X, Ling L, Li H, Ou Y, Shi X, Lu Y, Zhang Y and Chen D: Houttuynia cordata polysaccharides ameliorate pneumonia severity and intestinal injury in mice with influenza virus infection. J Ethnopharmacol. 218:90–99. 2018.PubMed/NCBI View Article : Google Scholar
36	Klatzmann D and Abbas AK: The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 15:283–294. 2015.PubMed/NCBI View Article : Google Scholar
37	Zelaya H, Tada A, Vizoso-Pinto MG, Salva S, Kanmani P, Agüero G, Alvarez S, Kitazawa H and Villena J: Nasal priming with immunobiotic Lactobacillus rhamnosus, modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage. Inflamm Res. 64:589–602. 2015.PubMed/NCBI View Article : Google Scholar
38	Xu MJ, Liu BJ, Wang CL, Wang GH, Tian Y, Wang SH, Li J, Li PY, Zhang RH, Wei D, et al: Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. Int Immunopharmacol. 52:24–33. 2017.PubMed/NCBI View Article : Google Scholar
39	Liu M, Chen F, Liu T, Chen F, Liu S and Yang J: The role of oxidative stress in influenza virus infection. Microbes Infect. 19:580–586. 2017.PubMed/NCBI View Article : Google Scholar
40	Lee MS and Kim YJ: Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 76:447–480. 2007.PubMed/NCBI View Article : Google Scholar
41	Kawasaki T and Kawai T: Toll-like receptor signaling pathways. Front Immunol. 5(461)2014.PubMed/NCBI View Article : Google Scholar
42	Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, et al: CD14 is a coreceptor of toll-like receptors 7 and 9. J Exp Med. 207:2689–2701. 2010.PubMed/NCBI View Article : Google Scholar
43	Chen Z, Liu Y, Sun B, Li H, Dong J, Zhang L, Wang L, Wang P, Zhao Y and Chen C: Polyhydroxylated metallofullerenols stimulate IL-1β secretion of macrophage through TLRs/MyD88/NF-κB pathway and NLRP₃ inflammasome activation. Small. 10:2362–2372. 2014.PubMed/NCBI View Article : Google Scholar
44	Lee N, Wong CK, Hui DS, Lee SK, Wong RY, Ngai KL, Chan MC, Chu YJ, Ho AW, Lui GC, et al: Role of human Toll-like receptors in naturally occurring influenza A infections. Influenza Other Respir Viruses. 7:666–675. 2013.PubMed/NCBI View Article : Google Scholar
45	Terán-Cabanillas E, Montalvo-Corral M, Silva-Campa E, Caire-Juvera G, Moya-Camarena SY and Hernández J: Production of interferon α and β, pro-inflammatory cytokines and the expression of suppressor of cytokine signaling (SOCS) in obese subjects infected with influenza A/H1N1. Clin Nutr. 33:922–926. 2014.PubMed/NCBI View Article : Google Scholar
46	Li L, Wei K, Lu FG, Cai L, Zhang B, Zhang SY, Gao Q and Dai B: Effect of Maxing Shigan Decoction against type A influenza virus infection in mice induced by viral lung injury based on TLR4-MyD88-TRAF6 signal pathways. Chin Traditional Herbal Drugs. 48:1591–1596. 2017.
47	Lin CJ, Lin HJ, Chen TH, Hsu YA, Liu CS, Hwang GY and Wan L: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through Toll-Like receptor 9-induced interferon beta expression. PLoS One. 10(e0117602)2015.PubMed/NCBI View Article : Google Scholar
48	Liu R, He T, Zeng N, Chen T, Gou L and Liu JW: Mechanism of anti-influenza virus of volatile oil in Cinnamomi Ramulus and cinnamaldehyde. Chin Traditional Herbal Drugs. 44:1460–1464. 2013.